Cancer Advances Overview

  • Founded
  • 2008

Founded
  • Status
  • Private

  • Employees
  • 2

Employees
  • Latest Deal Type
  • Buyout/​LBO

  • Investors
  • 1

Cancer Advances General Information

Description

Developer of oncology drugs designed to improve the quality of life and extend the survival rate of patients with gastrointestinal cancers. The company's drug Polyclonal Antibody Stimulator is an immunomodulator that blocks the function of gastrin and slows down tumor growth, and the incidence of metastasis, and also changes the tumor microenvironment, enabling physicians to improve medical outcomes and improve the lives of their patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Westpark Corporate Center
  • Suite 105, 4364 South Alston Avenue
  • Durham, NC 27713
  • United States
+1 (919) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cancer Advances Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Buyout/LBO Completed Startup
To view Cancer Advances’s complete valuation and funding history, request access »

Cancer Advances Patents

Cancer Advances Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2018283284-A1 Compositions and methods for inducing humoral and cellular immunities against tumors and cancer Pending 15-Jun-2017 00000000
CA-3066756-A1 Compositions and methods for inducing humoral and cellular immunities against tumors and cancer Pending 15-Jun-2017 00000000
EP-3624841-A1 Compositions and methods for inducing humoral and cellular immunities against tumors and cancer Pending 15-Jun-2017 00000000
EP-3624841-A4 Compositions and methods for inducing humoral and cellular immunities against tumors and cancer Pending 15-Jun-2017 0000000000
JP-2020528449-A Compositions and methods for inducing humoral and cell-mediated immunity against tumors and cancers Pending 15-Jun-2017 A61K39/385 0
To view Cancer Advances’s complete patent history, request access »

Cancer Advances Executive Team (4)

Name Title Board Seat Contact Info
Allen Cato Ph.D Co-Founder, Chief Executive Officer & Chief Medical Officer
John Wingen Chief Financial Officer
Lynda Sutton President
You’re viewing 3 of 4 executive team members. Get the full list »

Cancer Advances Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cancer Advances Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cato BioVentures Corporate Venture Capital Majority 000 0000 000000 0
To view Cancer Advances’s complete investors history, request access »